Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 0.00% is 100% above its 3-year average of -65.91%, near the high end of its 3-year range (-5562.95%–42.31%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 642 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Artiva Biotherapeutics, Inc.
Market Cap
$346.15M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$353.35M
Net Profit Margin
-96.89%
TTM Avg
-148.47%
3Y Avg
-151.80%
5Y Avg
-119.69%
Market Cap
$354.20M
Net Profit Margin
8.59%
TTM Avg
7.90%
3Y Avg
10.47%
5Y Avg
19.48%
Market Cap
$355.03M
Net Profit Margin
-1091.82%
TTM Avg
-436.37%
3Y Avg
-220.06%
5Y Avg
-1750.93%
Market Cap
$337.51M
Net Profit Margin
69.34%
TTM Avg
-109.76%
3Y Avg
-150.31%
5Y Avg
-135.75%
Market Cap
$356.89M
Net Profit Margin
-184.60%
TTM Avg
-1235.34%
3Y Avg
-1300.41%
5Y Avg
-438.85%
Market Cap
$357.79M
Net Profit Margin
-5.49%
TTM Avg
-11.37%
3Y Avg
-410.78%
5Y Avg
-2049.25%
Market Cap
$330.79M
Net Profit Margin
-81.76%
TTM Avg
-64.66%
3Y Avg
-75.38%
5Y Avg
-73.80%
Market Cap
$361.15M
Net Profit Margin
-1786.27%
TTM Avg
-1435.22%
3Y Avg
-1851.09%
5Y Avg
-9692.20%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | $346.15M | 0.00% | 0.00% | 0.00% | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.35M | -96.89% | -148.47% | -151.80% | -119.69% |
| Embecta Corp. (EMBC)vs › | $354.20M | 8.59% | 7.90% | 10.47% | 19.48% |
| Opus Genetics, Inc. (IRD)vs › | $355.03M | -1091.82% | -436.37% | -220.06% | -1750.93% |
| Agenus Inc. (AGEN)vs › | $337.51M | 69.34% | -109.76% | -150.31% | -135.75% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $356.89M | -184.60% | -1235.34% | -1300.41% | -438.85% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $357.79M | -5.49% | -11.37% | -410.78% | -2049.25% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $330.79M | -81.76% | -64.66% | -75.38% | -73.80% |
| Ocugen, Inc. (OCGN)vs › | $361.15M | -1786.27% | -1435.22% | -1851.09% | -9692.20% |
| Cabaletta Bio, Inc. (CABA)vs › | $330.92M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | -5562.95% |
| 2023-12-31 | -510.55% |
| 2023-09-30 | 42.31% |
| 2023-06-30 | -322.68% |
| 2023-03-31 | -1690.29% |
